Metformin supports the antidiabetic effect of a sodium glucose cotransporter 2 inhibitor by suppressing endogenous glucose production in diabetic mice

Diabetes

Volumn 64, Issue 1, 2015, Pages 284-290

  Neschen, Susanne ^a,b   Scheerer, Markus ^a,b   Seelig, Anett ^a,b   Huypens, Peter ^a,b   Schultheiss, Jürgen ^a   Wu, Moya ^a,b   Wurst, Wolfgang ^a,c,d,e   Rathkolb, Birgit ^a   Suhre, Karsten ^a,f   Wolf, Eckhard ^g   Beckers, Johannes ^a,b,d   De Angelis, Martin Hrabé ^a,b,d  

^a INSTITUTE OF EPIDEMIOLOGY   (Germany)

^b GERMAN CENTER FOR DIABETES RESEARCH DZD   (Germany)

^c MAX PLANCK INSTITUTE OF PSYCHIATRY   (Germany)

^d TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^e GERMAN CENTER FOR NEURODEGENERATIVE DISEASES DZNE   (Germany)

^f WEILL CORNELL MEDICAL COLLEGE   (Qatar)

^g UNIVERSITY OF MUNICH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AVE 2268; METFORMIN; SODIUM GLUCOSE COTRANSPORTER 2 INHIBITOR; UNCLASSIFIED DRUG; ANTIDIABETIC AGENT; AVE2268; GLUCOSE; GLUCOSIDE; GLYCOSYLATED HEMOGLOBIN; HBA(1C) PROTEIN, MOUSE; SLC5A2 PROTEIN, MOUSE; SODIUM GLUCOSE COTRANSPORTER 2;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIDIABETIC ACTIVITY; ARTICLE; COMBINATION CHEMOTHERAPY; DRUG EFFICACY; DRUG MECHANISM; GLUCONEOGENESIS; GLUCOSE BLOOD LEVEL; HYPERGLYCEMIA; MALE; MONOTHERAPY; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; ANIMAL; ANTAGONISTS AND INHIBITORS; BIOSYNTHESIS; DIABETES MELLITUS, EXPERIMENTAL; DIABETES MELLITUS, TYPE 2; DISEASE MODEL; DRUG COMBINATION; GENETICS; GLUCOSE CLAMP TECHNIQUE; KNOCKOUT MOUSE; METABOLISM; MOUSE MUTANT; OBESITY;

ANIMALS; DIABETES MELLITUS, EXPERIMENTAL; DIABETES MELLITUS, TYPE 2; DISEASE MODELS, ANIMAL; DRUG THERAPY, COMBINATION; GLUCOSE; GLUCOSE CLAMP TECHNIQUE; GLUCOSIDES; HEMOGLOBIN A, GLYCOSYLATED; HYPERGLYCEMIA; HYPOGLYCEMIC AGENTS; METFORMIN; MICE, KNOCKOUT; MICE, OBESE; OBESITY; SODIUM-GLUCOSE TRANSPORTER 2;

EID: 84919958374     PISSN: 00121797     EISSN: 1939327X     Source Type: Journal    
DOI: 10.2337/db14-0393     Document Type: Article

References (19)

1. Consoli A, Nurjhan N, Capani F, Gerich J. Predominant role of gluconeogenesis in increased hepatic glucose production in NIDDM. Diabetes 1989;38: 550-557
2. Turner RC, Cull CA, Frighi V, Holman RR; UK Prospective Diabetes Study (UKPDS) Group. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: Progressive requirement for multiple therapies (UKPDS 49). JAMA 1999;281:2005-2012
3. DeFronzo RA, Eldor R, Abdul-Ghani M. Pathophysiologic approach to therapy in patients with newly diagnosed type 2 diabetes. Diabetes Care 2013;36 (Suppl. 2):S127-S138
4. Bailey CJ. Renal glucose reabsorption inhibitors to treat diabetes. Trends Pharmacol Sci 2011;32:63-71
5. Jurczak MJ, Lee HY, Birkenfeld AL, et al. SGLT2 deletion improves glucose homeostasis and preserves pancreatic beta-Cell function. Diabetes 2011;60: 890-898
6. Henry RR, Murray AV, Marmolejo MH, Hennicken D, Ptaszynska A, List JF. Dapagliflozin, metformin XR, or both: Initial pharmacotherapy for type 2 diabetes, a randomised controlled trial. Int J Clin Pract 2012;66:446-456
7. Witters LA. The blooming of the French lilac. J Clin Invest 2001;108:1105-1107
8. Shaw RJ, Lamia KA, Vasquez D, et al. The kinase LKB1 mediates glucose homeostasis in liver and therapeutic effects of metformin. Science 2005;310: 1642-1646
9. Nathan DM, Buse JB, Davidson MB, et al.; American Diabetes Association; European Association for Study of Diabetes. Medical management of hyperglycemia in type 2 diabetes: A consensus algorithm for the initiation and adjustment of therapy: A consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2009;32:193-203
10. Kilov G, Leow S, Thomas M. SGLT2 inhibition with dapagliflozin - a novel approach for the management of type 2 diabetes. Aust Fam Physician 2013;42: 706-710
11. Ferrannini E, Muscelli E, Frascerra S, et al. Metabolic response to sodiumglucose cotransporter 2 inhibition in type 2 diabetic patients. J Clin Invest 2014; 124:499-508
12. Merovci A, Solis-Herrera C, Daniele G, et al. Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production. J Clin Invest 2014;124:509-514
13. Bailey CJ, Gross JL, Pieters A, Bastien A, List JF. Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: A randomised, double-blind, placebo-Controlled trial. Lancet 2010; 375:2223-2233
14. Konstantopoulos N, Molero JC, McGee SL, et al. Methazolamide is a new hepatic insulin sensitizer that lowers blood glucose in vivo. Diabetes 2012;61:2146-2154
15. Liang Y, Arakawa K, Ueta K, et al. Effect of canagliflozin on renal threshold for glucose, glycemia, and body weight in normal and diabetic animal models. PLoS ONE 2012;7:e30555
16. Kim JH, Sen S, Avery CS, et al. Genetic analysis of a new mouse model for non-Insulin-Dependent diabetes. Genomics 2001;74:273-286
17. Bickel M, Brummerhop H, Frick W, et al. Effects of AVE2268, a substituted glycopyranoside, on urinary glucose excretion and blood glucose in mice and rats. Arzneimittelforschung 2008;58:574-580
18. Kiefer FW, Neschen S, Pfau B, et al. Osteopontin deficiency protects against obesity-Induced hepatic steatosis and attenuates glucose production in mice. Diabetologia 2011;54:2132-2142
19. Zinker BMX, Liu H, Cai C, et al. Dapagliflozin corrects plasma glucose levels after acute and chronic treatment: A mechanistic examination of glucose fluxes and transcription profiles (Abstract). Diabetologia 2012;55:S309